about pulmatrix

Pulmatrix is a clinical stage pharmaceutical company developing a broad new class of inhaled therapies that treat and prevent infectious and progressive respiratory diseases to meet significant unmet medical need. We are approaching respiratory diseases in a fundamentally new way through simple and safe therapies that harness the airway and lungs own natural biophysical properties and host defense mechanisms.

With technology and insights originating from the laboratories of Harvard University and the Massachusetts Institute of Technology, the potential of Pulmatrix to make a difference in how respiratory disease is treated and controlled has attracted a world class team of industry professionals, leading scientists, and accomplished investors with extensive experience in the life sciences sector working together to drive the development of a completely new therapeutic paradigm for many infectious and progressive respiratory diseases including influenza, asthma, rhinovirus, and chronic pulmonary diseases.